

# REFORM trial clinical summary – 24 month results<sup>1</sup>

<b>Trial name:</b>	REFORM
<b>Company:</b>	Cook Medical
<b>Product:</b>	Formula™ Renal Balloon-Expandable Stent
<b>Lead investigator:</b>	Dr. Robert Bersin, Seattle Cardiology and Swedish Medical Center
<b>Trial design:</b>	Prospective, single-arm study at seven investigative sites in U.S.
<b>Patients enrolled:</b>	100
<b>Core lab adjudication:</b>	Yes
<b>General lesion requirement:</b>	De novo or restenotic ostial lesions
<b>Primary endpoint:</b>	Primary patency at nine months
<b>Secondary endpoints:</b>	Target lesion revascularization (TLR) rate and changes in hypertension, renal function and blood pressure medication levels
<b>Method:</b>	Stenting following suboptimal angioplasty
<b>Patient demographics:</b>	
Age (years)	72 ± 10
Diabetes	43%
Hypertension	97%
Systolic blood pressure (mm Hg)	150 ± 21
eGFR (mL/min)	61 ± 29
<b>Lesion characteristics:</b>	
Lesion length (mm)	7.7 ± 3.6
Reference vessel diameter (mm)	5.3 ± 0.9
Diameter stenosis (preprocedure)	57 ± 14%
Moderate to severe calcification	37%



**Formula™**

**RENAL BALLOON-EXPANDABLE STENT**

# REFORM trial clinical summary – 24 month results<sup>1</sup>

	9 Months	24 Months
Major adverse events (TLRs only)*	2.2%	5.7%
Significant embolic events	0.0%	0.0%
Primary patency <sup>†</sup>	91.7%	–
Systolic blood pressure (mm Hg) – preprocedure = 150 ± 21	141 ± 21 ( <i>P</i> < 0.01)	136 ± 20 ( <i>P</i> < 0.01)
Patients with ≥ 10 mm Hg decrease in systolic blood pressure	45%	55%
Patients with decrease in <b>dosage</b> of blood pressure medications	30%	40%
Patients with decrease in <b>number</b> of blood pressure medications	23%	40%
Clinically meaningful improvement in renal function <sup>‡</sup>	11.9%	19.6%

\* Per patient.

† Defined as freedom from TLR and < 60% stenosis by duplex ultrasound (peak systolic velocity < 225 cm/sec and renal aortic ratio ≤ 3.5) or angiography. Patency assessed at nine months only.

‡ Defined as ≥ 25% increase in eGFR or ≥ 0.5 mg/dL decrease in serum creatinine.

1. Bersin R. Results through 2-year follow-up from the REFORM clinical study. Presented at: EuroPCR; May 17-20, 2011; Paris, France.